Dexcom
(NSDQ:DXCM) said Friday that its G6 continuous glucose monitor system has received the CE Mark for use during pregnancy, and will be available soon, starting with the United Kingdom in Spring 2020.
Glucose levels are hard to manage in pregnancy due to the increasing need for and resistance to insulin. Poorly controlled glucose levels in pregnant women with Type 1, Type 2 or gestational diabetes can lead to serious problems for the mother and child, and the solutions for managing diabetes during pregnancy are currently limited.
The CE Mark of the Dexcom G6 for pregnant women provides more choice for both healthcare professionals and patients to manage their disease, according to the San Diego–based company.
“We are excited that the Dexcom G6 has received the CE mark in the EU for use during pregnancy. It is a life-changing development for this group of patients and highlights our continued mission to innovate on behalf of everyone living with diabetes,” said Erik Bjorkman, Dexcom general manager and vice president for EMEA, in a news release.
“Women with Type 1 or Type 2 in pregnancy or those with gestational diabetes usually require six or more fingersticks per day. These are required during the night, before meals, as well as after eating meals and snacks,” added Dr. Helen Murphy, professor of medicine at the University of East Anglia in Norwich, UK. “CGM eliminates the need for fingersticks and provides patients with regular updates and alerts throughout the day and night. This allows them to manage their glucose levels with confidence during pregnancy and helps them to deliver healthy babies.”
